Small Organic Molecule Disruptors of Cav3.2 - USP5 Interactions Reverse Inflammatory and Neuropathic Pain

Molecular Pain

Volumn 11, Issue , 2015, Pages

  Gadotti, Vinicius M ^a   Caballero, Agustin Garcia ^a   Berger, N Daniel ^a   Gladding, Clare M ^b   Chen, Lina ^a   Pfeifer, Tom A ^b   Zamponi, Gerald W ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b Centre for Drug Research and Development   (Canada)

Author keywords

Chronic pain; Gossypetin; Suramin; T type channels; USP5

Indexed keywords

CALCIUM CHANNEL; FLAVONOID; FREUND ADJUVANT; SURAMIN; ANALGESIC AGENT; CACNA1H PROTEIN, MOUSE; CALCIUM CHANNEL T TYPE; DEUBIQUITINASE; USP5 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMICAL ANALYSIS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DIABETIC NEUROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DISRUPTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERSENSITIVITY; INFLAMMATION; MECHANICAL HYPERALGESIA; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PARTIAL SCIATIC NERVE LIGATION INJURY; PRIORITY JOURNAL; VISCERAL PAIN; WRITHING TEST; ANIMAL; HUMAN; HYPERALGESIA; KNOCKOUT MOUSE; METABOLISM; NEURALGIA; PATHOPHYSIOLOGY; SENSORY NERVE CELL; SPINAL GANGLION;

ANALGESICS; ANIMALS; CALCIUM CHANNELS, T-TYPE; GANGLIA, SPINAL; HUMANS; HYPERALGESIA; INFLAMMATION; MICE; MICE, KNOCKOUT; NEURALGIA; NEURONS, AFFERENT; SURAMIN; UBIQUITIN-SPECIFIC PROTEASES;

EID: 84928235984     PISSN: None     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/s12990-015-0011-8     Document Type: Article

References (47)

1. Jacus MO, Uebele VN, Renger JJ, Todorovic SM. Presynaptic Cav3.2 channels regulate excitatory neurotransmission in nociceptive dorsal horn neurons. J Neurosci. 2012;32:9374–82.
2. Waxman SG, Zamponi GW. Regulating excitability of peripheral afferents: emerging ion channel targets. Nat Neurosci. 2014;17:153–63.
3. Todorovic SM, Jevtovic-Todorovic V., Regulation of T-type calcium channels in the peripheral pain pathway. Channels. 2007;1:238–45.
4. Todorovic SM, Meyenburg A, Jevtovic-Todorovic V., Mechanical and thermal antinociception in rats following systemic administration of mibefradil, a T-type calcium channel blocker. Brain Res. 2002;951:336–40.
5. Dogrul A, Gardell LR, Ossipov MH, Tulunay FC, Lai J, Porreca F., Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain. 2003;105:159–68.
6. Francois A, Kerckhove N, Meleine M, Alloui A, Barrere C, Gelot A, State-dependent properties of a new T-type calcium channel blocker enhance Ca(V)3.2 selectivity and support analgesic effects. Pain. 2013;154:283–93.
7. Choe W, Messinger RB, Leach E, Eckle VS, Obradovic A, Salajegheh R, TTA-P2 is a potent and selective blocker of T-type calcium channels in rat sensory neurons and a novel antinociceptive agent. Mol Pharmacol. 2011;80:900–10.
8. Bladen C, Gunduz MG, Simsek R, Safak C, Zamponi GW. Synthesis and evaluation of 1,4-dihydropyridine derivatives with calcium channel blocking activity. Pflugers Archiv. 2014;466:1355–63.
9. Bladen C, Gadotti VM, Gunduz MG, Berger ND, Simsek R, Safak C, 1,4-Dihydropyridine derivatives with T-type calcium channel blocking activity attenuate inflammatory and neuropathic pain. Pflugers Archiv. 2015. (epub ahead of print doi:10.1007/s00424-014-1566-3).
10. Bourinet E, Alloui A, Monteil A, Barrere C, Couette B, Poirot O, Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J. 2005;24:315–24.
11. Jagodic MM, Pathirathna S, Nelson MT, Mancuso S, Joksovic PM, Rosenberg ER, Cell-specific alterations of T-type calcium current in painful diabetic neuropathy enhance excitability of sensory neurons. J Neurosci. 2007;27:3305–16.
12. Jagodic MM, Pathirathna S, Joksovic PM, Lee W, Nelson MT, Naik AK, Upregulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J Neurophysiol. 2008;99:3151–6.
13. Marger F, Gelot A, Alloui A, Matricon J, Ferrer JF, Barrere C, T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome. PNAS. 2011;108:11268–73.
14. Messinger RB, Naik AK, Jagodic MM, Nelson MT, Lee WY, Choe WJ, In vivo silencing of the Ca(V)3.2 T-type calcium channels in sensory neurons alleviates hyperalgesia in rats with streptozocin-induced diabetic neuropathy. Pain. 2009;145:184–95.
15. Garcia-Caballero A, Gadotti VM, Stemkowski P, Weiss N, Souza IA, Hodgkinson V, The deubiquitinating enzyme USP5 modulates neuropathic and inflammatory pain by enhancing Cav3.2 channel activity. Neuron. 2014;83:1144–58.
16. Besche HC, Haas W, Gygi SP, Goldberg AL. Isolation of mammalian 26S proteasomes and p97/VCP complexes using the ubiquitin-like domain from HHR23B reveals novel proteasome-associated proteins. Biochemistry. 2009;48:2538–49.
17. Komander D, Clague MJ, Urbe S., Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol. 2009;10:550–63.
18. Voogd TE, Vansterkenburg EL, Wilting J, Janssen LH. Recent research on the biological activity of suramin. Pharmacol Rev. 1993;45:177–203.
19. Hausmann R, Rettinger J, Gerevich Z, Meis S, Kassack MU, Illes P, The suramin analog 4,4′,4′,4‴-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2Χ3 receptors: subtype selectivity is determined by location of sulfonic acid groups. Mol Pharmacol. 2006;69:2058–67.
20. Salvamani S, Gunasekaran B, Shaharuddin NA, Ahmad SA, Shukor MY. Antiartherosclerotic effects of plant flavonoids. BioMed Res Int. 2014;2014:480258.
21. Chen JH, Tsai CW, Wang CP, Lin HH. Anti-atherosclerotic potential of gossypetin via inhibiting LDL oxidation and foam cell formation. Tox Appl Pharm. 2013;272:313–24.
22. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817–24.
23. Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology. 1995;45:1115–21.
24. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacol Therapeut. 2008;120:1–34.
25. Daousi C, Benbow SJ, Woodward A, MacFarlane IA. The natural history of chronic painful peripheral neuropathy in a community diabetes population. Diab Med. 2006;23:1021–4.
26. Davies M, Brophy S, Williams R, Taylor A., The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518–22.
27. Ziegler D, Rathmann W, Meisinger C, Dickhaus T, Mielck A, Group KS. Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA Myocardial Infarction Registry. Eur J Pain. 2009;13:582–7.
28. Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I., Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care. 2009;32:1479–84.
29. Srinath AI, Walter C, Newara MC, Szigethy EM. Pain management in patients with inflammatory bowel disease: insights for the clinician. Therap Adv Gastroenterol. 2012;5:339–57.
30. Ali MK, Ashraf A, Biswas NN, Karmakar UK, Afroz S., Antinociceptive, anti-inflammatory and antidiarrheal activities of ethanolic calyx extract of Hibiscus sabdariffa Linn. (Malvaceae) in mice. Chinese J integr med. 2011;9:626–31.
31. Driessen B, Reimann W, Selve N, Friderichs E, Bultmann R., Antinociceptive effect of intrathecally administered P2-purinoceptor antagonists in rats. Brain Res. 1994;666:182–8.
32. Wu Y, Willcockson HH, Maixner W, Light AR. Suramin inhibits spinal cord microglia activation and long-term hyperalgesia induced by formalin injection. J Pain. 2004;5:48–55.
33. Sawynok J, Reid A., Peripheral adenosine 5′-triphosphate enhances nociception in the formalin test via activation of a purinergic p2X receptor. Eur J Pharmacol. 1997;330:115–21.
34. Li N, Lu ZY, Yu LH, Burnstock G, Deng XM, Ma B., Inhibition of G protein-coupled P2Y2 receptor induced analgesia in a rat model of trigeminal neuropathic pain. Mol Pain. 2014;10:21.
35. Spelta V, Jiang LH, Surprenant A, North RA. Kinetics of antagonist actions at rat P2Χ2/3 heteromeric receptors. Br J Pharmacol. 2002;135:1524–30.
36. Grubb BD, Evans RJ. Characterization of cultured dorsal root ganglion neuron P2X receptors. Eur J Neurosci. 1999;11:149–54.
37. McGeary RP, Bennett AJ, Tran QB, Cosgrove KL, Ross BP. Suramin: clinical uses and structure-activity relationships. Mini Rev Med Chem. 2008;8:1384–94.
38. Eisenberger MA, Sinibaldi VJ, Reyno LM, Sridhara R, Jodrell DI, Zuhowski EG, Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol. 1995;13:2174–86.
39. Garcia-Schurmann JM, Schulze H, Haupt G, Pastor J, Allolio B, Senge T., Suramin treatment in hormone- and chemotherapy-refractory prostate cancer. Urology. 1999;53:535–41.
40. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000;18:1440–50.
41. Allaert FA. Prevention of recurrent cystitis in women: double-blind, placebo-controlled study of Hibiscus sabdariffa L. extract. La Lettre de l'Infectiologue. 2010;25:56–60.
42. Ferreira J, Campos MM, Pesquero JB, Araujo RC, Bader M, Calixto JB. Evidence for the participation of kinins in Freund's adjuvant-induced inflammatory and nociceptive responses in kinin B1 and B2 receptor knockout mice. Neuropharmacology. 2001;41:1006–12.
43. Malmberg AB, Basbaum AI. Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain. 1998;76:215–22.
44. Ribeiro RA, Vale ML, Thomazzi SM, Paschoalato AB, Poole S, Ferreira SH, Involvement of resident macrophages and mast cells in the writhing nociceptive response induced by zymosan and acetic acid in mice. Eur J Pharmacol. 2000;387:111–8.
45. Koster R, Anderson M, Debeer EJ. Acetic acid for analgesic screening. Fed Proc. 1959;18:412.
46. Tjølsen A, Hole K., Animal Models of Analgesia. In: Dickenson A, Besson JM, editors. Berlin Springer; 1997.
47. Hylden JL, Wilcox GL. Intrathecal morphine in mice: a new technique. Eur J Pharmacol. 1980;67:313–6.